Dr. Graff Discusses the Treatment of Prostate Cancer

Julie Graff, MD
Published: Tuesday, Jan 09, 2018



Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Currently there is one FDA-approved immunotherapy, sipuleucel-T (Provenge). There are other vaccines in development, as well as trials of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, Graff adds.

In the next 5 to 10 years, Graff predicts that results from these studies will create more options for the treatment of patients with prostate cancer.
SELECTED
LANGUAGE


Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.

Currently there is one FDA-approved immunotherapy, sipuleucel-T (Provenge). There are other vaccines in development, as well as trials of checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, Graff adds.

In the next 5 to 10 years, Graff predicts that results from these studies will create more options for the treatment of patients with prostate cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x